公开(公告)号：US20110092451A1

公开(公告)日：2011-04-21

申请号：US12933291

申请日：2009-03-18

申请人： Yvan Guindon

发明人： Yvan Guindon

IPC分类号： A61K31/7076 ,  A61K31/7056 ,  A61K31/7068 ,  C07H19/04 ,  C07H19/16 ,  C07H19/06 ,  A61P31/14 ,  A61P31/18 ,  A61P35/00 ,  A61P31/16

CPC分类号： C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H19/23

摘要： The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3′ position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.

摘要翻译： 本发明包括可用作抗病毒剂或抗肿瘤剂的化合物。 这些化合物包含核苷酸类似物，其包含在3'位上具有四元中心的四氢呋喃基或四氢噻吩基。 核苷酸类似物可用于抑制癌症或病毒。 因此，本发明的化合物可用于治疗，预防和/或抑制与癌症和病毒相关的疾病或病症。 因此，本发明还包括包含该化合物的药物制剂和使用该化合物和制剂抑制病毒或肿瘤并治疗，预防或抑制前述疾病的方法。

公开(公告)号：US20100093737A1

公开(公告)日：2010-04-15

申请号：US12523193

申请日：2008-01-17

申请人： Yvan Guindon

发明人： Yvan Guindon

IPC分类号： A61K31/53 ,  C07D253/075 ,  C07D473/18 ,  C07D405/02 ,  A61P31/12 ,  C07K5/09 ,  A61K31/522 ,  A61K31/506 ,  C12N5/02 ,  A61P35/04

CPC分类号： C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20

摘要： The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3′ position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.

摘要翻译： 本发明包括可用作抗病毒剂或抗肿瘤剂的化合物。 这些化合物包含核苷酸类似物，其包含在3'位上具有四元中心的四氢呋喃基或四氢噻吩基。 核苷酸类似物可以用于抑制癌症或病毒。 因此，本发明的化合物可用于治疗，预防和/或抑制与癌症和病毒相关的疾病或病症。 因此，本发明还包括包含该化合物的药物制剂和使用该化合物和制剂抑制病毒或肿瘤并治疗，预防或抑制前述疾病的方法。

公开(公告)号：US20100015654A1

公开(公告)日：2010-01-21

申请号：US11914512

申请日：2006-05-15

申请人： Andre Veillette ,  Romain Roncagalli

发明人： Andre Veillette ,  Romain Roncagalli

IPC分类号： C12Q1/02 ,  C07H21/02 ,  C12N5/02

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/14 ,  G01N33/5047 ,  G01N33/5088 ,  G01N33/6872 ,  G01N2500/00

摘要： The present invention relates to the identification EAT-2 and ERT as novel therapeutic targets for the modulation of innate immune cell functions. More particularly the present invention describes novel methods for modulating innate immune cells-mediated immune response, useful in the treatment of cancer, infectious diseases as well as autoimmune diseases. The invention also features EAT-2 deficient and overexpressing transgenic animals, screening assays to identify agents that modulate EAT-2 and ERT activity or expression as well as methods of treatments comprising a modulation of NK cells function

摘要翻译： 本发明涉及鉴定EAT-2和ERT作为调节先天免疫细胞功能的新型治疗靶标。 更具体地，本发明描述了用于调节先天免疫细胞介导的免疫应答的新方法，其可用于治疗癌症，感染性疾病以及自身免疫性疾病。 本发明还具有EAT-2缺陷和过表达的转基因动物，筛选测定以鉴定调节EAT-2和ERT活性或表达的试剂以及包含NK细胞功能调节的治疗方法

公开(公告)号：US20130316964A1

公开(公告)日：2013-11-28

申请号：US13961313

申请日：2013-08-07

申请人： Hazel H. SZETO ,  Peter W. SCHILLER

发明人： Hazel H. SZETO ,  Peter W. SCHILLER

IPC分类号： C07K5/11 ,  C07K7/06

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K5/0817 ,  C07K5/10 ,  C07K5/1019

摘要： The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

公开(公告)号：US20130149311A1

公开(公告)日：2013-06-13

申请号：US13696668

申请日：2011-05-06

申请人： Tarik Moroy ,  Cyrus Khandanpour ,  Lothar Vassen ,  Ehssan Sharif-Askari

发明人： Tarik Moroy ,  Cyrus Khandanpour ,  Lothar Vassen ,  Ehssan Sharif-Askari

IPC分类号： A61K39/395 ,  A61K31/454 ,  A61K38/10 ,  A61K31/7088

CPC分类号： A61K39/3955 ,  A61K31/454 ,  A61K31/7088 ,  A61K38/10 ,  A61K38/1709 ,  C12Q1/6876 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/74 ,  G01N2500/04

摘要： Methods, uses and kits for increasing the number of hematopoietic stem cells (HSCs) in a biological system, such as for increasing the number of HSCs in the bone marrow and/or blood of a subject, based on the modulation of growth factor independence 1b (Gfi1b), are disclosed.

摘要翻译： 基于生长因子独立性1b的调节，用于增加生物系统中造血干细胞（HSCs）数量的方法，用途和试剂盒，例如用于增加受试者的骨髓和/或血液中的HSC的数量 （Gfi1b）。

公开(公告)号：US08404646B2

公开(公告)日：2013-03-26

申请号：US13247648

申请日：2011-09-28

申请人： Peter W. Schiller ,  Hazel H. Szeto ,  Kesheng Zhao

发明人： Peter W. Schiller ,  Hazel H. Szeto ,  Kesheng Zhao

IPC分类号： A61K38/07

CPC分类号： A61K38/07 ,  A61K38/03 ,  C07K5/1008 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1024

摘要： The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.

公开(公告)号：US20110003315A1

公开(公告)日：2011-01-06

申请号：US12300148

申请日：2007-05-08

申请人： Nabil G. Seidah ,  Jean Davignon ,  Geneviève Dubuc ,  Lise Bernier ,  Michel Tremblay

发明人： Nabil G. Seidah ,  Jean Davignon ,  Geneviève Dubuc ,  Lise Bernier ,  Michel Tremblay

IPC分类号： G01N33/567 ,  C12N9/50 ,  C12N5/10 ,  C12Q1/37

CPC分类号： G01N33/5008 ,  A61K38/00 ,  C07K16/40 ,  C07K2319/01 ,  C07K2319/03 ,  C12N9/6424

摘要： A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.

摘要翻译： 包含以下顺序的嵌合体蛋白质：信号肽，由SEQ ID NO：38的35至696位的氨基酸残基组成的前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型前蛋白（PCSK9）序列，跨膜结构域和胞质结构域 ，其中所述细胞溶质（CT）结构域包含能够将蛋白从细胞膜再循环到内体的序列。

公开(公告)号：US07446189B1

公开(公告)日：2008-11-04

申请号：US09980762

申请日：2000-04-27

申请人： David B. Weiner ,  Michael G. Agadjanyan ,  Rafick P. Sekaly ,  Mark Holterman

发明人： David B. Weiner ,  Michael G. Agadjanyan ,  Rafick P. Sekaly ,  Mark Holterman

IPC分类号： C07H21/00 ,  C07H21/04 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/00 ,  C12N15/11

CPC分类号： C07K14/70532 ,  A61K39/00

摘要： Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.

摘要翻译： 公开了改进的疫苗和使用该疫苗的方法。公开了用于治疗患有自身免疫性疾病或移植物的个体的免疫抑制组合物及其使用方法。

公开(公告)号：US07211424B1

公开(公告)日：2007-05-01

申请号：US09830837

申请日：1999-11-04

申请人： Nabil G. Seidah ,  Michel Chretien ,  Mieczyslaw Marcinkiewicz

发明人： Nabil G. Seidah ,  Michel Chretien ,  Mieczyslaw Marcinkiewicz

IPC分类号： C12N9/64 ,  C12N15/57 ,  C12N15/79 ,  C07K1/00 ,  C07K16/00

CPC分类号： C12N9/6424

摘要： Using RT-PCR and degenerate oligonucleotides derived from the active site residues of subtilisin-kexin-like serine proteinases, we have identified a highly conserved and phylogenetically ancestral human, rat and mouse type-I membrane-bound proteinase called subtilisin-kexin-isozyme-1 (SKI-1). Computer data bank searches reveals that human SKI-1 was previously cloned but with no identified function. A SKI-1 processed fragment is secreted in culture media in a soluble form. In vitro studies suggest that SKI-1 is a Ca2+-dependent serine proteinase exhibiting a wide pH optimum for cleavage of proBDNF. Peptides mimicking SKI-1 cleavages sites are also disclosed. SKI-1 prosegment has an ex vivo inhibitory effect on SKI-1 activity. The prosegment is also processed and secreted in culture media. One of its fragments is found tightly associated with the SKI-1 soluble form. Therapeutic applications for SKI-1 inhibitors are disclosed.

摘要翻译： 使用RT-PCR和衍生自枯草杆菌蛋白酶 - 类克隆丝氨酸蛋白酶的活性位点残基的简并寡核苷酸，我们确定了一种高度保守和系统发育的祖先人类，大鼠和小鼠I型膜结合蛋白酶，称为枯草杆菌蛋白酶 - 1（SKI-1）。 计算机数据库搜索显示人类SKI-1以前被克隆，但没有识别功能。 SKI-1处理的片段以可溶形式分泌在培养基中。 体外研究表明，SKI-1是表现出对于proBDNF的切割具有宽pH最适的Ca 2+ 2 +依赖性丝氨酸蛋白酶。 还公开了模拟SKI-1切割位点的肽。 SKI-1 prosegment具有对SKI-1活性的离体抑制作用。 散文也在文化媒体中被处理和分发。 其中一个片段被发现与SKI-1可溶形式紧密相关。 公开了SKI-1抑制剂的治疗应用。

公开(公告)号：US20200038472A1

公开(公告)日：2020-02-06

申请号：US16569573

申请日：2019-09-12

申请人： Cornell Research Foundation, Inc. ,  Institut De Recherches Cliniques de Montreal

发明人： Hazel H. Szeto ,  Peter W. Schiller ,  Kesheng Zhao

IPC分类号： A61K38/07 ,  A61K38/03 ,  C07K5/103 ,  C07K5/107 ,  C07K5/11 ,  C07K5/117

摘要： The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.